Tissue inhibitor of metalloproteinase-1 and -3 improves cardiac function in an ischemic cardiomyopathy model rat

Tissue Eng Part A. 2014 Nov;20(21-22):3073-84. doi: 10.1089/ten.TEA.2013.0763. Epub 2014 Jun 16.

Abstract

Matrix metalloproteinases (MMPs) and a family of tissue inhibitors of metalloproteinases (TIMPs) may contribute to myocardial remodeling in heart failure. TIMPs are the main inhibitors of MMPs and have other MMP-independent functions. Because little is known of the role of TIMPs in the heart, we examined the effects of TIMPs on cardiac fibroblasts (CFs) and cardiomyocytes. In vitro, TIMP-1-4 enhanced smooth muscle actin (SMA) expression in CFs, and TIMP-1 and TIMP-3 enhanced the expression of phosphorylated Smad-3 and phosphorylated transforming growth factor (TGF)-β type 1 receptor in CFs; this effect was inhibited by TGF-β receptor blocker SB-505124. TIMPs-1, -3, and -4 also inhibited the FAK, AKT, and ERK pathways that induce cardiac hypertrophy. TIMP-1 and TIMP-2 suppressed apoptosis in cardiomyocytes; in contrast, TIMP-4 induced apoptosis in CFs. TIMP-2 stimulated collagen synthesis. Collagen gels containing TIMP-1 or TIMP-3, which exhibit cardioprotective effects in vitro, were transplanted to the left ventricular anterior wall of a rat heart model of myocardial infarction. Gel-released TIMP-1 and TIMP-3 significantly improved cardiac function and myocardial remodeling and enhanced SMA expression in the infarcted area in ischemic cardiomyopathy model rats. Further, the transplantation of TIMP-1 or TIMP-3 gels inhibited apoptosis in the ischemic myocardium and reduced MMP-2 activity. TIMPs may be an ideal target of cardiac regeneration therapy.

MeSH terms

  • Animals
  • Cardiomyopathies / complications
  • Cardiomyopathies / drug therapy*
  • Cardiomyopathies / pathology
  • Cardiotonic Agents / administration & dosage
  • Drug Implants / administration & dosage*
  • Male
  • Myocardial Ischemia / complications
  • Myocardial Ischemia / drug therapy*
  • Myocardial Ischemia / pathology
  • Rats
  • Rats, Sprague-Dawley
  • Recovery of Function / drug effects
  • Tissue Inhibitor of Metalloproteinase-1 / administration & dosage*
  • Tissue Inhibitor of Metalloproteinase-3 / administration & dosage*
  • Treatment Outcome
  • Ventricular Remodeling / drug effects*

Substances

  • Cardiotonic Agents
  • Drug Implants
  • Tissue Inhibitor of Metalloproteinase-1
  • Tissue Inhibitor of Metalloproteinase-3